*Based on BIOSOLVE-II, -II/-III and -IV, for patient populations see study details;
1. According to the Magnesium 2,000 program; 2. Torzewski J. Safety and performance of Magmaris at 36-months: BIOSOLVE-IV first cohort . Presented at: EuroPCR; 2022; ClinicalTrials.gov: NCT02817802.; Target Lesion Failure (TLF) defined as a composite of Cardiac Death, Target-Vessel Myocardial Infarction (TV-MI), emergent Coronary Artery Bypass Grafting (eCABG) and Clinically-Driven Target Lesion Revascularization (CD-TLR).
Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies.
Magmaris is currently not available in the US.
© 2022 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.